FibroDynamx
Preclinical biotechnology company developing anti-fibrotic and regenerative therapeutics for skin by leveraging comparative regenerative biology of reindeer antler skin to identify and validate drug targets and therapeutic candidates.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Preclinical regenerative skin therapeutic candidate (preclinical)
Therapeutic candidate developed to reduce scar formation and promote regenerative skin healing; demonstrated increased hair and gland regeneration in a mouse skin wound model.
Preclinical regenerative skin therapeutic candidate (preclinical)
Therapeutic candidate developed to reduce scar formation and promote regenerative skin healing; demonstrated increased hair and gland regeneration in a mouse skin wound model.
Expertise Areas
- Anti-fibrotic therapeutics discovery
- Skin regeneration and wound healing
- Single-cell multi-omics analysis
- Preclinical efficacy testing in wound models
Key Technologies
- Single-cell multi-omics
- In vivo preclinical wound-healing models
- Comparative model systems
- Bioinformatics and large-scale dataset analysis
News & Updates
Single-cell multi-omics showed that antler skin fibroblasts resemble fetal-like regenerative states while back skin fibroblasts express pro-fibrotic inflammatory mediators; study nominates decoupling fibroblast-immune interactions as an approach to mitigate scarring.
Single-cell multi-omics showed that antler skin fibroblasts resemble fetal-like regenerative states while back skin fibroblasts express pro-fibrotic inflammatory mediators; study nominates decoupling fibroblast-immune interactions as an approach to mitigate scarring.